Tempus ECG-AF vs Viz HCM
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for integrating into routine ECG analysis workflows to support earlier identification and follow-up for AF prevention in a specific, at-risk demographic.
View Tempus ECG-AF →Choose Viz HCM if…
Choose Viz HCM if your institution requires real-time detection of suspected Hypertrophic Cardiomyopathy (HCM) from ECGs and robust, AI-powered care coordination. This tool is best suited for streamlining the diagnostic pathway and automatically directing patients to appropriate specialists, significantly reducing time to diagnosis and treatment for HCM.
View Viz HCM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Viz HCM |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Unknown |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz HCMViz HCM offers a cloud-based platform with mobile-based alerts and seamless integration into existing clinical workflows, EHR, and PACS systems, including specific EMR integrations with Epic and Cerner. In contrast, Tempus ECG-AF explicitly states it does not have a dedicated user interface, which limits direct clinician interaction and workflow integration.
Clinical Value
Viz HCMWhile both are FDA-cleared and address significant cardiac conditions, Viz HCM focuses on real-time detection of Hypertrophic Cardiomyopathy (HCM) and actively coordinates cardiac care, significantly reducing diagnosis and treatment time for a critical condition. Tempus ECG-AF predicts the risk of Atrial Fibrillation (AF) within 12 months, which is valuable for earlier identification, but Viz HCM's impact on immediate care coordination for HCM, a leading cause of sudden cardiac death, suggests a more direct and potentially life-saving clinical impact.
Pricing & Value
TieBoth tools have identical CMS reimbursement available for CPT codes 0764T and 0765T, with a Medicare rate of $128.90 effective January 1, 2025. Neither tool provides specific pricing details beyond 'contact vendor' or 'subscription-based,' making a direct comparison of overall cost-effectiveness impossible with the given information. Therefore, their value propositions from a reimbursement standpoint are equal.
Enterprise Readiness
Viz HCMBoth tools are FDA-cleared, HIPAA compliant, and provide BAAs, which are essential for enterprise use. However, Viz HCM's explicit mention of a 'Cloud-based platform' and 'seamless integration with existing clinical workflows, EHR, and PACS systems,' including integrations with leading EMRs like Epic and Cerner, indicates a more modern and robust enterprise deployment strategy. Tempus ECG-AF's description of integration into 'healthcare facility systems' is less specific regarding scalability and depth of integration.
Innovation
Viz HCMBoth leverage AI for ECG analysis, which is innovative. Tempus ECG-AF's innovation lies in predicting future AF risk. However, Viz HCM extends its innovation beyond detection to include real-time alerts, mobile notifications, and automated direction of patients to appropriate care specialists, actively streamlining the entire care coordination workflow. Viz HCM also highlights being the 'only approved HCM algorithm on the market,' showcasing a unique market position.
Support & Docs
Viz HCMViz HCM offers a publicly accessible 'Knowledge Base' with common questions, troubleshooting guides, and product overviews, demonstrating a structured approach to support documentation. Tempus ECG-AF provides contact information for its support team but does not explicitly detail a public knowledge base or extensive self-service documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Viz HCM |
|---|---|---|
| Tool Name | Tempus ECG-AF | Viz HCM |
| Company | Tempus AI, Inc. | Viz.ai |
| Primary Use Case | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | Detects suspected Hypertrophic Cardiomyopathy (HCM) and coordinates cardiac care. |
| Target Patient Population/Criteria | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified |
| Key Technology | AI-based algorithm for 12-lead ECG analysis | AI-powered ECG analysis |
| Reimbursement | CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). | CMS reimbursement available for CPT codes 0764T and 0765T (national payment rate $128.90, effective Jan 1, 2025). |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Viz HCM.